The Wegovy Golden Shot: Separating the Evidence from the Hype

Where the 'golden shot' idea comes from, and what STEP 1 actually found

The phrase 'golden shot' entered popular usage as a shorthand for the dose or moment at which people on Wegovy feel the medicine working most noticeably. It is not a clinical term. What sits behind it, though, is real: the STEP 1 trial results, published in the New England Journal of Medicine in 2021, were striking enough to catch the attention of clinicians, regulators and the public simultaneously.

In that trial, participants receiving semaglutide 2.4mg weekly alongside lifestyle support lost an average of around 15% of their body weight over 68 weeks. That is not a small number in the context of obesity treatment. For context, a 5% reduction is considered clinically meaningful for conditions like type 2 diabetes, high blood pressure and joint strain. A 15% average puts many participants well past that threshold.

The catch (and it is an important one) is that 'average' conceals a wide spread. Some participants lost considerably more; others less. The trial population was specific: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, without type 2 diabetes. Results in real-world practice, across a broader and more varied population, tend to cluster closer to the lower end of the trial range. That is not a criticism of the medicine; it is just how medicine works outside controlled conditions. You can read more about semaglutide's evidence base to understand how the trial programme was structured.

The 7.2mg approval, does a higher dose deliver the 'golden' result?

In January 2026 the MHRA approved a higher 7.2mg maintenance dose of Wegovy, and on 14 April 2026 they approved a dedicated single-dose 7.2mg pen, one pre-set weekly injection with a built-in covered needle that locks after use. Trial data for 7.2mg reported average weight loss of approximately 20.7% over 72 weeks, bringing results closer to those seen with tirzepatide at its highest licensed dose.

This is where the 'golden shot' idea picks up renewed energy: people read 20.7% and assume a higher dose is simply better. The reality is more measured. The titration schedule still starts at 0.25mg and works upward in roughly four-weekly steps, guided by tolerability. The 7.2mg dose is the ceiling, not the starting point, and it is not suitable for everyone. The MHRA's approval for the 7.2mg pen applies to adults with a BMI of 30 or above; the lower 2.4mg maintenance dose remains standard for many patients.

If you are curious about how to take your Wegovy shot correctly, our guide covers technique step by step.

Side effects, the dose-increase period, and what to expect

The period after each dose increase is often when side effects are most noticeable, which may partly explain why some people describe a particular injection as the point things 'clicked'. Gastrointestinal effects (nausea, loose stools, constipation, indigestion) are the most commonly reported, and they tend to be most pronounced in the first week or two after stepping up. For most people they ease as the body adjusts.

The NHS medicines page for semaglutide lists the full side-effect profile alongside practical advice on managing them. Pancreatitis is a less common but more serious concern: the MHRA highlighted acute pancreatitis as a recognised risk in a Drug Safety Update for GLP-1 medicines in January 2026. Severe, persistent stomach pain that spreads toward the back is the key warning sign and warrants same-day medical attention.

A practical note on routine: keeping the pen in the fridge door and injecting on the same day each week makes both adherence and side-effect tracking easier. If you want to make sure you are getting your injection right from the start, our step-by-step guide to doing your Wegovy shot walks you through the full process. If you are ever unsure whether a dose went in properly, there is straightforward guidance on confirming your Wegovy shot landed correctly.

It is also worth knowing what to expect in the hours and day following each injection. Many people find that planning the day around mild nausea is easier once they know what is normal versus what warrants a call to their prescriber. Our page on the day after a Wegovy shot covers this in detail.

Who can access Wegovy, and what the 'golden shot' frame gets wrong

The 'golden shot' framing implies there is a single, definitive moment of transformation. The clinical picture is slower and more individual than that. Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

NICE recommends semaglutide for weight management only within specialist weight management services, for a maximum of two years, and only for adults with a BMI of 35 or above alongside at least one comorbidity (lower thresholds apply for certain ethnic backgrounds). For the NHS route, that typically means a referral and a waiting list. Private treatment through a regulated pharmacy is an alternative for people who do not meet those criteria or prefer not to wait, provided a prescriber confirms suitability. Our guide to where Wegovy can be obtained in the UK explains what legitimate access looks like and how to avoid counterfeit supply.

The honest summary: Wegovy's trial results are among the strongest seen for a weight-management medicine in years. Whether those results translate into your own 'golden' experience depends on your starting point, how your body responds, and the lifestyle changes you make alongside treatment. A prescriber is the right person to help you weigh that up. To explore whether Wegovy could be clinically appropriate for you, speak to our prescribers through a free consultation.